Actelion Drug Patent Portfolio

Actelion owns 6 orange book drugs protected by 18 US patents with Veletri having the least patent protection, holding only 2 patents. And Uptravi with maximum patent protection, holding 6 patents. Given below is the list of Actelion's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10821108 Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide 01 Dec, 2036
Active
US10828298 Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy]-N-(methylsulfonyl)acetamide 01 Dec, 2036
Active
US8791122 Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and method for producing the same 01 Aug, 2030
Active
US9284280 Use of form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide 25 Jun, 2030
Active
US9173881 Therapeutic compositions containing macitentan 12 Aug, 2029
Active
US8268847 Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor 18 Apr, 2029
Active
US8367685 Stable pharmaceutical compositions comprising a pyrimidine-sulfamide 04 Oct, 2028
Active
US7959945 Dispersible bosentan tablet 28 Dec, 2027
Active
US9265762 Stable pharmaceutical compositions comprising a pyrimidine-sulfamide 29 May, 2027
Active
US8318802 Epoprostenol formulation and method of making thereof 15 Mar, 2027
Active
US8598227 Epoprostenol formulation and method of making thereof 02 Feb, 2027
Active
US7205302 Heterocyclic compound derivatives and medicines 31 Oct, 2026
Active
US10946015 Stable pharmaceutical compositions comprising a pyrimidine-sulfamide 11 Sep, 2026
Active
US8309126 Dispersible bosentan tablet 15 May, 2026
Active
US7094781 Sulfamides and their use as endothelin receptor antagonists 05 Dec, 2025
Active
US5292740 Sulfonamides 20 Nov, 2015 Expired
US5525616 Method of inhibiting glycolipid synthesis 11 Jun, 2013 Expired
US5472969 Method of inhibiting glycolipid synthesis 13 May, 2013 Expired


Given below is the list of recent legal activities going on the following drug patents of Actelion.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 15 May, 2024 US8318802
Payment of Maintenance Fee, 12th Year, Large Entity 01 May, 2024 US8309126
Payment of Maintenance Fee, 4th Year, Large Entity 24 Apr, 2024 US10828298
Payment of Maintenance Fee, 4th Year, Large Entity 17 Apr, 2024 US10821108
Court Processing Terminated 02 Apr, 2024 US7205302
Payment of Maintenance Fee, 12th Year, Large Entity 06 Mar, 2024 US8268847
Payment of Maintenance Fee, 12th Year, Large Entity 06 Mar, 2024 US8268847
Payment of Maintenance Fee, 8th Year, Large Entity 30 Aug, 2023 US9284280
Payment of Maintenance Fee, 8th Year, Large Entity 09 Aug, 2023 US9265762
Payment of Maintenance Fee, 8th Year, Large Entity 19 Apr, 2023 US9173881
Payment of Maintenance Fee, 12th Year, Large Entity 30 Nov, 2022 US7959945
Payment of Maintenance Fee, 8th Year, Large Entity 12 Jan, 2022 US8791122
Patent Term Extension Certificate 12 Nov, 2021 US7205302
Payment of Maintenance Fee, 8th Year, Large Entity 19 May, 2021 US8598227
Recordation of Patent Grant Mailed 16 Mar, 2021 US10946015


Actelion Drug Patents' Oppositions Filed in EPO

Actelion drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Aug 11, 2016, by Generics (U.K.) Limited. This opposition was filed on patent number EP07763188A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP17186415A Oct, 2020 Generics [UK] Limited Granted and Under Opposition
EP17191033A Jul, 2020 Stada-Arzneimittel Aktiengesellschaft Granted and Under Opposition
EP17191033A Jul, 2020 Generics (UK) Ltd Granted and Under Opposition
EP17191033A Jul, 2020 Aera A/S Granted and Under Opposition
EP10792183A Sep, 2018 Hexal AG Granted and Under Opposition
EP10792183A Sep, 2018 Generics [UK] Ltd Granted and Under Opposition
EP10792183A Sep, 2018 Alfred E. Tiefenbacher (GmbH & Co. KG) Granted and Under Opposition
EP09786912A Jul, 2018 Hexal AG Granted and Under Opposition
EP09786912A Jul, 2018 Teva Pharmaceutical Industries Ltd Granted and Under Opposition
EP09786912A Jul, 2018 STADA Arzneimittel AG Granted and Under Opposition
EP09786912A Jul, 2018 Alfred E. Tiefenbacher (GmbH & Co. KG) Granted and Under Opposition
EP09786912A Jul, 2018 Generics (UK) Ltd Granted and Under Opposition
EP07763188A Aug, 2016 Generics (U.K.) Limited Revoked


Actelion's Family Patents

Actelion drugs have patent protection in a total of 41 countries. It's US patent count contributes only to 14.8% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Actelion Drug List

Given below is the complete list of Actelion's drugs and the patents protecting them.


1. Opsumit

Opsumit is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8268847 Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor 18 Apr, 2029
(4 years from now)
Active
US8367685 Stable pharmaceutical compositions comprising a pyrimidine-sulfamide 04 Oct, 2028
(3 years from now)
Active
US9265762 Stable pharmaceutical compositions comprising a pyrimidine-sulfamide 29 May, 2027
(2 years from now)
Active
US10946015 Stable pharmaceutical compositions comprising a pyrimidine-sulfamide 11 Sep, 2026
(1 year, 11 months from now)
Active
US7094781 Sulfamides and their use as endothelin receptor antagonists 05 Dec, 2025
(1 year, 1 month from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Opsumit's drug page


2. Opsynvi

Opsynvi is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8268847 Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor 18 Apr, 2029
(4 years from now)
Active
US10946015 Stable pharmaceutical compositions comprising a pyrimidine-sulfamide 11 Sep, 2026
(1 year, 11 months from now)
Active
US7094781 Sulfamides and their use as endothelin receptor antagonists 05 Dec, 2025
(1 year, 1 month from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Opsynvi's drug page


3. Tracleer

Tracleer is protected by 3 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7959945 Dispersible bosentan tablet 28 Dec, 2027
(3 years from now)
Active
US8309126 Dispersible bosentan tablet 15 May, 2026
(1 year, 7 months from now)
Active
US5292740 Sulfonamides 20 Nov, 2015
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tracleer's drug page


4. Uptravi

Uptravi is protected by 6 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10821108 Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide 01 Dec, 2036
(12 years from now)
Active
US10828298 Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy]-N-(methylsulfonyl)acetamide 01 Dec, 2036
(12 years from now)
Active
US8791122 Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and method for producing the same 01 Aug, 2030
(5 years from now)
Active
US9284280 Use of form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide 25 Jun, 2030
(5 years from now)
Active
US9173881 Therapeutic compositions containing macitentan 12 Aug, 2029
(4 years from now)
Active
US7205302 Heterocyclic compound derivatives and medicines 31 Oct, 2026
(2 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Uptravi's drug page


5. Veletri

Veletri is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8318802 Epoprostenol formulation and method of making thereof 15 Mar, 2027
(2 years from now)
Active
US8598227 Epoprostenol formulation and method of making thereof 02 Feb, 2027
(2 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Veletri's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Zavesca

Zavesca is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5525616 Method of inhibiting glycolipid synthesis 11 Jun, 2013
(11 years ago)
Expired
US5472969 Method of inhibiting glycolipid synthesis 13 May, 2013
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zavesca's drug page